Form 15-12G Premier, Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-36092
PREMIER, INC.
(Exact name of registrant as specified in its charter)
13520 Ballantyne Corporate Place
Charlotte,
North Carolina 28277
(704) 357-0022
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Class A Common Stock, $0.01 par value
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
| Rule 12g-4(a)(1) |
☒ | |
| Rule 12g-4(a)(2) |
☐ | |
| Rule 12h-3(b)(1)(i) |
☒ | |
| Rule 12h-3(b)(1)(ii) |
☐ | |
| Rule 15d-6 |
☐ | |
| Rule 15d-22(b) |
☐ |
Approximate number of holders of record as of the certification or notice date: One.
Pursuant to the requirements of the Securities Exchange Act of 1934, Premier, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
| PREMIER, INC. | ||||||||
| Date: | December 5, 2025 | By: | /s/ David Klatsky | |||||
| Name: David Klatsky | ||||||||
| Title: Senior Vice President, General Counsel | ||||||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crypto News: Remittix Announces 300 Million RTX Burn at Launch as JPMorgan Brings Two Tokenized Funds to Solana, Building the Case for a $300 SOL Price Prediction
- Monster Energy and Call of Duty® Take Over Cosm Los Angeles for Immersive Modern Warfare® 4 Launch Celebration
- Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share